Quick Summary
Bydureon BCise (exenatide) and Byetta (exenatide) are both glp-1 receptor agonists. In clinical trials, Byetta showed greater weight loss (2.8% vs 2.3%).
See the comparison table below for detailed side-by-side data.
Bydureon BCise vs Byetta: Full Comparison
| Feature | Bydureon BCise(exenatide extended-release) | Byetta(exenatide) |
|---|---|---|
| Active Ingredient | exenatide | exenatide |
| Drug Class | GLP-1 receptor agonist | GLP-1 receptor agonist |
| Manufacturer | AstraZeneca | AstraZeneca |
| FDA Approved | 2012-01-27 | 2005-04-28 |
| Approved Indications |
|
|
| Route | subcutaneous injection | subcutaneous injection |
| Frequency | Once weekly | Twice daily (within 60 min before meals) |
| Starting Dose | 2 mg weekly | 5 mcg twice daily |
| Maintenance Dose | 2 mg weekly | 10 mcg twice daily |
| Max Dose | 2 mg weekly | 10 mcg twice daily |
| Weight Loss (%) | 2.3% | 2.8% |
| A1C Reduction | 1.3% | 0.8% |
| Key Trial | DURATION-1 (30 weeks) | AC2993 Phase 3 (30 weeks) |
| List Price | $800-$950/month | $800-$900/month |
| With Insurance | $25-$100/month (varies by plan) | $25-$100/month (varies by plan) |
| Savings Card | Limited savings programs available | Limited savings programs available |
Side Effects: Bydureon BCise vs Byetta
| Side Effect | Bydureon BCise | Byetta |
|---|---|---|
| Nausea | 11% | 44% |
| Diarrhea | 9% | 13% |
| Injection site nodule | 10-17% | Not reported |
| Headache | 8% | 9% |
| Vomiting | 4% | 13% |
| Constipation | 6% | Not reported |
| Pancreatitis (rare) | <1% | <1% |
| Dizziness | Not reported | 9% |
| Dyspepsia | Not reported | 6% |
| Jittery feeling | Not reported | 4% |
Severity scale: 1 (mild) to 5 (serious). Based on FDA prescribing information and clinical trial data.
Related Comparisons
Frequently Asked Questions
Sources & References
This content is for informational purposes only and is not medical advice. Always consult your healthcare provider before making medication decisions. See our full medical disclaimer.